| Literature DB >> 32800382 |
Alexander M Newman1, Mehreen Arshad2.
Abstract
The prevalence of multidrug-resistant organisms is increasing worldwide, posing a unique challenge to global health care systems. Novel approaches are needed to combat the spread of infection with these organisms. The enteric microbiome, and in particular the resistome, offers a unique target in both the prevention of infection with these organisms and the acquisition and spread within the community. We highlight a novel approach to combat multidrug-resistant organisms: the use of prebiotics, probiotics, and synbiotics to manipulate the microbiome and resistome. This review summarizes the published literature and clinical trials related to these products to date, with a focus on efficacious trials. It highlights the probable mechanism of action for each product, as well as its safety profile in selective populations. Ultimately, although further research is needed before a definitive statement can be made on the efficacy of any of these 3 interventions, the literature to date offers new hope and a new tool in the arsenal in the fight against bacterial drug resistance.Entities:
Keywords: microbiome; multidrug-resistant organisms; prebiotic; probiotic; resistome; synbiotic
Mesh:
Substances:
Year: 2020 PMID: 32800382 PMCID: PMC7904027 DOI: 10.1016/j.clinthera.2020.06.011
Source DB: PubMed Journal: Clin Ther ISSN: 0149-2918 Impact factor: 3.393